4 Healthcare Stock Stories Promoting Investment Wellness on Wednesday
VIVUS Inc. (NASDAQ:VVUS): Closing price $10.11
On Wednesday, Vivus announced new data published online in Diabetes Care showing the effects of Qsymia (phentermine and topiramate extended-release) capsules CIV, on the progression to type 2 diabetes. In the evaluation, high-risk overweight or obese patients suffering with prediabetes and/or metabolic syndrome who were taking Qsymia during a two-year period experienced reductions of as much as 78.7 percent in the annualized incidence rate of type 2 diabetes, along with to losing weight. The American Association of Clinical Endocrinologists recognizes obesity and prediabetes as significant risk factors for progression to diabetes and allied complications.